Published January 23, 2023
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses abrocitinib (Cibinqo), 200 mg, 100 mg, 50 mg, oral tablets.
- Indication: Cibinqo (abrocitinib) is indicated for the treatment of patients 12 years and older with refractory moderate-to-severe atopic dermatitis, including pruritus, who have had an inadequate response to other systemic drugs (e.g., steroid or biologic), or for whom these treatments are not advised.